{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:10Z","timestamp":1790409250235,"version":"4.1.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["14\/ICS\/B3042"],"award-info":[{"award-number":["14\/ICS\/B3042"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","award":["15\/SIRG\/3456"],"award-info":[{"award-number":["15\/SIRG\/3456"]}],"id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001602","name":"Taighde \u00c9ireann - Research Ireland","doi-asserted-by":"publisher","award":["19\/FFP\/6446"],"award-info":[{"award-number":["19\/FFP\/6446"]}],"id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019905","name":"Galway University Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001634","name":"University of Galway","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001634","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.intimp.2026.116222","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:19:02Z","timestamp":1772007542000},"page":"116222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity"],"prefix":"10.1016","volume":"175","author":[{"given":"Claire L.","family":"Feerick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Swan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh A.","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Treacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O'Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aideen E.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116222_bb0005","first-page":"31","article-title":"New developments in the treatment of multiple myeloma - clinical utility of daratumumab","volume":"11","author":"McEllistrim","year":"2017","journal-title":"Biologics"},{"key":"10.1016\/j.intimp.2026.116222_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/2040620719854171","article-title":"Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma","volume":"10","author":"Swan","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/cei.13594","article-title":"Bone marrow-derived mesenchymal stem cells inhibit CD8(+) T cell immune responses via PD-1\/PD-L1 pathway in multiple myeloma","volume":"205","author":"Liu","year":"2021","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116222_bb0020","first-page":"493","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat. Can."},{"issue":"11","key":"10.1016\/j.intimp.2026.116222_bb0025","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1182\/bloodadvances.2021006805","article-title":"Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses","volume":"6","author":"Daly","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0030","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1859263","article-title":"Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis","volume":"10","author":"Naicker","year":"2021","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41408-024-01191-8","article-title":"CAR-T cell therapy in multiple myeloma: current status and future challenges","volume":"14","author":"Swan","year":"2024","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.intimp.2026.116222_bb0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/2643-3230.BCD-23-0176","article-title":"An embarrassment of riches: three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0045","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.cell.2013.12.041","article-title":"Sensitizing protective tumor microenvironments to antibody-mediated therapy","volume":"156","author":"Pallasch","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2026.116222_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020226","article-title":"Alterations of NK cell phenotype in the disease course of multiple myeloma","volume":"13","author":"Pazina","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.intimp.2026.116222_bb0055","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/eji.201344272","article-title":"Effect of tumor cells and tumor microenvironment on NK-cell function","volume":"44","author":"Vitale","year":"2014","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116222_bb0060","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0065","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12032-007-0007-y","article-title":"Clinical stage-depending decrease of NK cell activity in multiple myeloma patients","volume":"24","author":"Jurisic","year":"2007","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","article-title":"Harnessing natural killer cells for the treatment of multiple myeloma","volume":"49","author":"Clara","year":"2022","journal-title":"Semin. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2026.116222_bb0075","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/2040620716657993","article-title":"Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab","volume":"7","author":"Einsele","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.intimp.2026.116222_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02551","article-title":"Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, Elotuzumab in Multiple Myeloma","volume":"9","author":"Campbell","year":"2018","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.116222_bb0085","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/2326-6066.CIR-18-0579","article-title":"Enhanced SLAMF7 homotypic interactions by Elotuzumab improves NK cell killing of multiple myeloma","volume":"7","author":"Pazina","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116222_bb0090","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1158\/1535-7163.MCT-17-0998","article-title":"Antibody-dependent cellular phagocytosis by macrophages is a novel mechanism of action of Elotuzumab","volume":"17","author":"Kurdi","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"9","key":"10.1016\/j.intimp.2026.116222_bb0095","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-07-4246","article-title":"CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma","volume":"14","author":"Hsi","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.intimp.2026.116222_bb0100","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1182\/blood-2007-08-107292","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","volume":"112","author":"Tai","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.intimp.2026.116222_bb0105","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood-2010-03-272765","article-title":"Effect of FCGR2A and FCGR3A variants on CLL outcome","volume":"116","author":"Dornan","year":"2010","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.intimp.2026.116222_bb0110","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2008-09-179754","article-title":"Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses","volume":"113","author":"Bruhns","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2026.116222_bb0115","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000350","article-title":"Beyond DNA damage: exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma","volume":"4","author":"Swan","year":"2020","journal-title":"Hemasphere"},{"issue":"22","key":"10.1016\/j.intimp.2026.116222_bb0120","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1158\/1078-0432.CCR-17-0895","article-title":"Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal Cancer","volume":"23","author":"Scurr","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2022.152212","article-title":"Low-dose cyclophosphamide combined with IL-2 inhibits tumor growth by decreasing regulatory T cells and increasing CD8+ T cells and natural killer cells in mice","volume":"227","author":"Tang","year":"2022","journal-title":"Immunobiology"},{"issue":"5","key":"10.1016\/j.intimp.2026.116222_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112475","article-title":"Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment","volume":"42","author":"Egan","year":"2023","journal-title":"Cell Rep."},{"issue":"9","key":"10.1016\/j.intimp.2026.116222_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110701","article-title":"Tumor-associated mesenchymal stromal cells modulate macrophage phagocytosis in stromal-rich colorectal cancer via PD-1 signaling","volume":"27","author":"Leonard","year":"2024","journal-title":"iScience"},{"issue":"11","key":"10.1016\/j.intimp.2026.116222_bb0140","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/2326-6066.CIR-17-0443","article-title":"Stromal cell PD-L1 inhibits CD8(+) T-cell antitumor immune responses and promotes Colon Cancer","volume":"6","author":"O'Malley","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2026.116222_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01849","article-title":"Arenavirus induced CCL5 expression causes NK cell-mediated melanoma regression","volume":"11","author":"Bhat","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116222_bb0150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00740","article-title":"FcgammaR binding and ADCC activity of human IgG Allotypes","volume":"11","author":"de Taeye","year":"2020","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0155","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200839","article-title":"The SIRPalpha-CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.intimp.2026.116222_bb0160","article-title":"Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"5","author":"Dimopoulos","year":"2021","journal-title":"Hemasphere"},{"issue":"19","key":"10.1016\/j.intimp.2026.116222_bb0165","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2026.116222_bb0170","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2026.116222_bb0175","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fimmu.2017.01124","article-title":"The molecular mechanism of natural killer cells function and its importance in Cancer immunotherapy","volume":"8","author":"Paul","year":"2017","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0180","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.116222_bb0185","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"25","key":"10.1016\/j.intimp.2026.116222_bb0190","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1182\/blood.2025029215","article-title":"An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden","volume":"146","author":"Meermeier","year":"2025","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.intimp.2026.116222_bb0195","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","article-title":"Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets","volume":"125","author":"Sehgal","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116222_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1271807","article-title":"Immunomodulation of NK, NKT and B\/T cell subtypes in relapsed\/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival","volume":"13","author":"Prabhala","year":"2023","journal-title":"Front. Oncol."},{"issue":"22","key":"10.1016\/j.intimp.2026.116222_bb0205","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-20-1781","article-title":"Immunomodulation in Pomalidomide, dexamethasone, and Daratumumab-treated patients with relapsed\/refractory multiple myeloma","volume":"26","author":"Pierceall","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116222_bb0210","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.2147\/OTT.S174640","article-title":"Update on elotuzumab for the treatment of relapsed\/refractory multiple myeloma: patients' selection and perspective","volume":"12","author":"Trudel","year":"2019","journal-title":"Onco. Targets Ther."},{"key":"10.1016\/j.intimp.2026.116222_bb0215","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0220","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov."},{"issue":"10","key":"10.1016\/j.intimp.2026.116222_bb0225","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1158\/1078-0432.CCR-19-1431","article-title":"First-in-human phase I study of ABBV-838, an antibody-drug conjugate targeting SLAMF7\/CS1 in patients with relapsed and refractory multiple myeloma","volume":"26","author":"Vij","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2026.116222_bb0230","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"issue":"7201","key":"10.1016\/j.intimp.2026.116222_bb0235","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.intimp.2026.116222_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.66","article-title":"Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4","volume":"5","author":"Bjorklund","year":"2015","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.intimp.2026.116222_bb0245","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1182\/blood-2018-01-828418","article-title":"CK1alpha and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma","volume":"132","author":"Patil","year":"2018","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0250","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.intimp.2026.116222_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020305","article-title":"Targeting CD47 as a novel immunotherapy for multiple myeloma","volume":"12","author":"Sun","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s42003-023-04615-6","article-title":"The DNA damage response pathway regulates the expression of the immune checkpoint CD47","volume":"6","author":"Ghantous","year":"2023","journal-title":"Commun. Biol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0265","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.intimp.2026.116222_bb0270","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41590-023-01671-2","article-title":"CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity","volume":"24","author":"Tang","year":"2023","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.intimp.2026.116222_bb0275","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1182\/bloodadvances.2019000010","article-title":"CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001\/CTRIAL-IE 16-02 study","volume":"3","author":"O'Dwyer","year":"2019","journal-title":"Blood Adv."},{"issue":"9","key":"10.1016\/j.intimp.2026.116222_bb0280","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/13543784.2021.1955103","article-title":"Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options","volume":"30","author":"Le Calvez","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/fon-2022-0975","article-title":"A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma","volume":"19","author":"Paul","year":"2023","journal-title":"Future Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116222_bb0290","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1158\/2326-6066.CIR-18-0367","article-title":"Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment","volume":"7","author":"Nath","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0295","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00262-014-1610-3","article-title":"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-alpha pathways","volume":"64","author":"Balasa","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.intimp.2026.116222_bb0300","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000881","article-title":"NK cell phenotype is associated with response and resistance to Daratumumab in relapsed\/refractory multiple myeloma","volume":"7","author":"Verkleij","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0305","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1200\/JCO.21.02815","article-title":"Elotuzumab plus Pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2026.116222_bb0310","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.70149","article-title":"Management of relapsed multiple myeloma: a British Society of Haematology and UK myeloma society guideline","author":"Jenner","year":"2025","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116222_bb0315","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0320","first-page":"245","article-title":"Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials","volume":"109","author":"Gentile","year":"2024","journal-title":"Haematologica"},{"issue":"21","key":"10.1016\/j.intimp.2026.116222_bb0325","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.intimp.2026.116222_bb0330","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood-2018-07-863829","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma","volume":"132","author":"Garderet","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.intimp.2026.116222_bb0335","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clml.2021.02.004","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for the treatment of relapsed\/refractory multiple myeloma: real-world analysis of the Pethema-GEM experience","volume":"21","author":"Rodriguez-Otero","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.intimp.2026.116222_bb0340","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00277-019-03649-3","article-title":"Pomalidomide, cyclophosphamide, and dexamethasone for relapsed\/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study","volume":"98","author":"Trudel","year":"2019","journal-title":"Ann. Hematol."},{"issue":"9","key":"10.1016\/j.intimp.2026.116222_bb0345","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1080\/10428194.2020.1805111","article-title":"A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed\/refractory multiple myeloma","volume":"61","author":"Van Oekelen","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.intimp.2026.116222_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0206-8","article-title":"Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE multiple myeloma trial","volume":"9","author":"Weisel","year":"2019","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.intimp.2026.116222_bb0355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.21873\/cdp.10293","article-title":"NK and T-lymphocyte kinetics predict outcome in myeloma patients treated with Elotuzumab, Lenalidomide plus Dexamethasone","volume":"4","author":"Suzuki","year":"2024","journal-title":"Cancer Diagn. Progn."},{"key":"10.1016\/j.intimp.2026.116222_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027235","article-title":"Inhibition of the CD47-SIRPalpha axis for cancer therapy: a systematic review and meta-analysis of emerging clinical data","volume":"13","author":"Son","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"Biomark. Res."},{"key":"10.1016\/j.intimp.2026.116222_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2026.116222_bb0375","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2021.09.013","article-title":"Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study","volume":"43","author":"Dhanasiri","year":"2021","journal-title":"Clin. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0380","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2022007985","article-title":"Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15","volume":"7","author":"Fernandez","year":"2023","journal-title":"Blood Adv."},{"issue":"4","key":"10.1016\/j.intimp.2026.116222_bb0385","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in Lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.116222_bb0390","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.intimp.2026.116222_bb0395","doi-asserted-by":"crossref","first-page":"308 e1","DOI":"10.1016\/j.jtct.2023.12.016","article-title":"Safety and efficacy of Teclistamab in patients with relapsed\/refractory multiple myeloma: a real-world experience","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.intimp.2026.116222_bb0400","article-title":"BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety and resistance mechanisms","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2026.116222_bb0405","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","article-title":"Comparative effectiveness of Teclistamab versus real-world physician's choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.intimp.2026.116222_bb0410","article-title":"Development of BCMA-targeted bispecific natural killer cell engagers for multiple myeloma treatment","volume":"13","author":"Zhang","year":"2024","journal-title":"Antibodies (Basel)"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926000652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:56:21Z","timestamp":1776164181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":82,"alternative-id":["S1567576926000652"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116222","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclophosphamide-pomalidomide combination alters the tumour cell secretome and enhances the anti-myeloma activity of elotuzumab through NK cell-mediated cytotoxicity","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116222"}}